Tetrabutylammonium Bromide Media Aza-Michael Addition of 1,2,3,6-Tetrahydrophthalimide to Symmetrical Fumaric Esters and Acrylic Esters under Solvent-Free Conditions
The aza-Michael addition of 1,2,3,6-tetrahydrophthalimide with symmetrical fumaric esters has been performed efficiently in a solvent-free system at 100 °C and using 1,4-diazabicyclo[2.2.2]octane (DABCO) as a base in the presence of tetrabutylammonium bromide (TBAB). The products were obtained in good to high yields within 2.5-7.0 h. This reaction worked well on linear alkyl fumarates and was not effective
This application relates to derivatives of hydrocarbon terpenes (e.g., myrcene or farnesene), to methods of making the derivatives, and to the use of the derivatives as surfactants.
Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery
申请人:ADEKA CORPORATION
公开号:US10734684B2
公开(公告)日:2020-08-04
Disclosed is a nonaqueous secondary battery having a nonaqueous electrolyte containing a lithium salt dissolved in an organic solvent, in which the positive electrode active material is preferably a manganese-containing, lithium transition metal oxide salt. The nonaqueous electrolyte contains at least one compound of general formula (1), preferably at least one compound of general formula (1′). The content of the compound of formula (1) or (1′) in the nonaqueous electrolyte is preferably 0.001 to 10 mass %. The symbols in formulae (1) and (1′) are as defined in the description.
Process for the production of silyl carboxylate monomers
申请人:SIGMA COATINGS B.V.
公开号:EP1431301A1
公开(公告)日:2004-06-23
A process for the production of hydrocarbyl silyl unsaturated carboxylates of formula (I) is described,
wherein n represents a number of dihydrocarbylsiloxane units from 0 to 1000.
The process includes the reaction of an unsaturated carboxylic acid of formula (II)
with a hydrocarbyl silyl compound of formula (III)
the said reaction being carried out in the presence of a silaphilic catalyst.
[EN] PROTECTED FUMARIC ACID-BASED METABOLITES FOR THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] MÉTABOLITES À BASE D'ACIDE FUMARIQUE PROTÉGÉ DESTINÉS AU TRAITEMENT DE MALADIES AUTO-IMMUNES
申请人:NEUROVIVE PHARMACEUTICAL AB
公开号:WO2017060420A1
公开(公告)日:2017-04-13
The present invention provides novel cell-permeable fumarate acyl mercaptoethylamines (FAMs) which have cellular effects including induction of Nrf2 and inhibition of the NFkB pathway. These compounds have utility in medicine including their use in treatment of diseases such as Multiple sclerosis, Non-alcoholic Steatohepatitis, Psoriasis, Inflammatory Arthritis, Inflammatory Bowel Disease, Asthma, Chronic Obstructive Pulmonary Disease, Cancer, Parkinson's Disease, Alzheimer's Disease, Huntington's Disease and Amyotrophic Lateral Sclerosis.